Mesoblast (ASX:MSB) set the price for its Ryoncil mesenchymal stromal cell therapy as it seeks to launch the product in the coming weeks, according to a Thursday Australian bourse filing.
Ryoncil is a mesenchymal stromal cell therapy approved by the US Food and Drug Administration on Dec. 18, 2024, as the only therapy for pediatric patients aged two months and older, including adolescents and teenagers, with steroid-refractory acute graft versus host disease.
The firm said its commercial execution is underway, and it is engaging with the top 45 centers representing 80% of pediatric transplants in the US.
Mesoblast plans to further evaluate the immunomodulatory effects of Ryoncil on gastrointestinal inflammation in treating medically refractory pediatric Crohn's disease patients.
The company's shares rose past 2% in recent trading on Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.